Mirum Pharmaceuticals has reported data from a CAMEO study of its LIVMARLI (maralixibat) oral solution for the treatment of primary sclerosing cholangitis (PSC), an idiopathic chronic cholestatic liver disease.
The first proof-of-concept, open-label, 14-week study evaluated the tolerability, efficacy along with safety in patients with pruritus associated with PSC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It evaluated LIVMARLI in a total of 27 adults with PSC measuring pruritus, liver function and serum bile acid (sBA) levels.
Serum bile acid concentration and pruritus scores decreased over the 14-week period when treated with LIVMARLI.
A 40% reduction was also observed in participants whose sBA was elevated above normal at baseline and 70% improvement in pruritus in participants with an average pruritus score of ≥3 out of 10 at baseline.
The treatment emergent adverse events including diarrhea, abdominal pain and nausea were found to be generally tolerable and consistent with the expected IBAT inhibitors’ mechanism of action.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMirum Pharmaceuticals research and development head Pam Vig said: “The CAMEO study with LIVMARLI lays the foundation for the Phase IIb VISTAS study with volixibat, a minimally absorbed IBAT inhibitor, which is currently recruiting patients.
“We are grateful to the clinicians and patients who participated in the CAMEO study and thank them for their contribution.”
An estimated 50,000 people in Europe and 29,000 in the US suffer from PSC.
PSC is characterised by cholestasis, progressive inflammation, and destruction of bile ducts leading to cirrhosis, fibrosis, portal hypertension, cancer, and finally liver failure.
